Quality prescribing for respiratory illness 2024 to 2027 - draft guidance: consultation

We are consulting on this draft guide which aims to optimise treatment outcomes in the management of respiratory illness. Produced by Scottish Government, NHS Scotland and Experts by Experience, it builds on the 2018 to 2021 strategy. It promotes person-centred care, the 7-Steps process for medicine reviews and shared decision-making.


9. Respiratory Prescribing Data for NHS Health Boards

This chapter contains some top-level prescribing information comparing NHS Boards. Chart 12 below highlights the cost per treated patient which has decreased by £8.00 in NHS Scotland between 2021 and 2022.

Chart 12: Respiratory Costs per treated patient
Chart showing variance in respiratory costs per treated patient across all health boards and Scotland from 2020 to 2022. Overall Scotland trend is decreasing

Generic Prescribing

National and local guidance promotes branded prescribing of all inhalers excluding salbutamol inhalers. This ensures that the correct inhaler device and product is given to the individual (for example, formulations of inhaled corticosteroids differ in potency). Chart 13 shows prescribing of generic inhalers across health boards, showing improvements across all boards.

Chart 13: Proportion of generically prescribed inhalers as a proportion of all inhalers (excluding salbutamol)
Chart showing variance of generically prescribed inhalers across all health boards and Scotland from 2020 to 2022. Overall Scotland trend is decreasing

Contact

Email: EPandT@gov.scot

Back to top